BlackRock Acquires Welsh Carson Stake in Humana Clinics for $2.8 Billion

Advisers

The parties retained specialized investment banks and legal counsel to structure the transition of the primary care assets.

Humana engaged Guggenheim Securities, LLC as its lead financial adviser, according to the company’s October 13 press release. The insurer retained Goldman Sachs & Co. LLC as an additional financial adviser. Fried, Frank, Harris, Shriver & Jacobson LLP provided corporate legal counsel to Humana. The October 13 press release published by Humana and subsequent reporting by PE Hub on the same day indicate that the advisers representing BlackRock and Welsh, Carson, Anderson & Stowe are not disclosed. The specific legal entities conducting the antitrust analysis and handling the regulatory filings for the buyer remain private.

How the deal came about

The origins of the transaction trace back to Humana seeking an alternative funding mechanism for its growing medical delivery footprint.

Humana initially partnered with Welsh, Carson, Anderson & Stowe to fund the rapid rollout of specialized senior primary care centers. The original joint ventures required the private equity firm to supply the necessary capital for clinic construction and initial operating losses. The centers require several years to reach mature patient panels and profitability. The original agreements granted the private equity sponsor a put option. The contractual right guaranteed that the sponsor could demand Humana purchase the clinics at a later date. This requirement forced Humana to maintain substantial capital reserves.

Humana executives determined that maintaining the put option negatively impacted the corporate balance sheet. The liability increased the company’s cost of capital during a period when health insurance margins faced pressure from elevated medical utilization rates. The insurer initiated a process to restructure the joint venture and find a new financial partner willing to accept different terms. BlackRock, operating through its HPS Investment Partners division, presented a capital solution that removed the strict put obligation. HPS manages distinct credit and private equity vehicles with longer investment horizons than traditional buyout funds.

The negotiation focused heavily on protecting Humana’s balance sheet while ensuring BlackRock received adequate downside protection. The parties finalized an agreement where BlackRock acquires the exact equity interest held by the Welsh, Carson, Anderson & Stowe funds. Humana does not receive any cash proceeds from the $2.8 billion purchase price, according to the October 13 Form 8-K. The insurer also does not contribute new equity capital at closing. The transaction simply swaps the financial partner and rewrites the governing documents of the joint venture to favor the insurer’s long-term capital strategy.

The health insurance provider maintains absolute operational control over the medical centers. CenterWell manages patient care, physician employment, and clinical workflows across the entire portfolio. The operational continuity ensures Medicare Advantage members experience no disruption in their primary care services. The structure isolates the clinical operations from the financial engineering occurring at the holding company level.

Valuation and comparables

Financial metrics defining the specific performance of the joint venture remain outside the public domain.

Humana and BlackRock chose not to publish the transaction valuation multiples. The October 13 Form 8-K and press release omit figures for the joint venture’s aggregate revenue, earnings before interest, taxes, depreciation, and amortization, or patient revenue run rates. The implied Enterprise Value to EBITDA multiple is not disclosed. The Price to Earnings ratio is not disclosed. The lack of operational data prevents direct numerical comparisons to recent public market healthcare services acquisitions.

Historically, primary care acquisition multiples rely heavily on the number of Medicare Advantage lives managed under value-based care contracts. Deals in the sector routinely command high revenue multiples when the target clinics demonstrate a mature capability to manage total medical costs. CVS Health acquired Oak Street Health in 2023 for roughly $10.6 billion. That transaction valued the primary care operator at multiple times its forward revenue projections. Walgreens Boots Alliance previously invested billions into VillageMD to secure a large primary care footprint. The specific clinic economics of the CenterWell portfolio differ from those peers because Humana guarantees a high volume of its own insurance members to the joint venture locations.

The $2.8 billion valuation applies exclusively to the majority equity stake sold by Welsh, Carson, Anderson & Stowe. The figure establishes a baseline for the minimum capital deployed by HPS Investment Partners. The transaction lacked a public auction process. No rival bids or alternative bidders emerged in the financial press prior to the October 13 announcement, according to coverage by Reuters and Dow Jones Newswires. The bilateral nature of the secondary buyout suggests BlackRock preempted broader market interest by offering the exact structural changes Humana demanded.

Financing and structure

The acquisition relies entirely on capital sourced from specialized private market vehicles.

Investment vehicles managed by HPS Investment Partners will fund the entirety of the equity consideration. The October 13 Humana Form 8-K states that specific third-party acquisition debt packages are not disclosed. The parties did not reveal the leverage levels utilized by the acquiring funds. Private equity transactions typically employ secured debt to enhance equity returns. The absence of disclosed debt terms indicates HPS may rely on its own private credit capabilities to structure the financing internally.

The revised joint venture agreement eliminates the traditional put option. The change fundamentally alters the risk profile for the financial sponsor. CenterWell agreed to provide minimum-return protections for BlackRock to compensate for the lost liquidity guarantee. The October 13 Form 8-K notes that Humana will record these specific protections as a derivative instrument at fair value on its balance sheet. The precise mathematical formula calculating the minimum return is not disclosed.

The contract establishes a clear sequence for eventual liquidity. CenterWell holds a call option to begin purchasing individual clinics from the joint venture starting in 2028. The October 13 Humana press release confirms this right allows the insurer to gradually acquire full ownership of the centers as they reach mature profitability. The phased approach prevents a sudden, massive cash outlay.

BlackRock retains a distinct exit mechanism if Humana declines to exercise its purchase rights. The October 13 Form 8-K details that if CenterWell has not purchased all clinics by the end of 2033, BlackRock has the right to initiate a third-party sale of the remaining assets. CenterWell retains a right of first offer in that scenario. The structure ensures BlackRock can ultimately force a liquidity event after a seven-year hold period.

The new venture intends to deploy additional capital over the next two years. The funds will support ongoing clinic operations, new construction, and potential add-on acquisitions. The October 13 press release states the exact financial figure of this future commitment is not disclosed. The continued capital injection demonstrates BlackRock’s mandate extends beyond passive ownership of the existing asset base.

Humana assured investors the transaction protects its near-term earnings targets. The October 13 Form 8-K reaffirmed the company’s full-year 2026 adjusted earnings per share guidance floor of at least $9.00. The filing explicitly notes the $2.8 billion equity transfer will have no material impact on the 2026 adjusted earnings guidance.

Risks, conditions and key dates

The transaction timeline incorporates regulatory reviews and specific contractual milestones over a seven-year horizon.

• October 13, 2026: Humana, Welsh, Carson, Anderson & Stowe, and BlackRock execute the definitive agreement for the $2.8 billion equity transfer. Humana files the Form 8-K detailing the removal of the put option and the implementation of the minimum-return derivative instrument.
• Fourth Quarter of 2026: The parties expect to close the transaction. The timeline depends on clearing customary closing conditions. The deal requires federal and state regulatory clearances. The Hart-Scott-Rodino Antitrust Improvements Act mandates a waiting period for the Department of Justice and the Federal Trade Commission to review the secondary buyout.
• 2028: CenterWell gains the contractual right to begin executing its call option. The medical operator can start purchasing individual clinics from the joint venture pool as specific patient panels reach maturity.
• December 31, 2033: The final deadline for CenterWell to purchase the remaining clinical assets under its own discretion.
• Post-2033: BlackRock gains the authority to initiate a third-party sale of any clinics remaining in the joint venture. Humana’s CenterWell division holds a right of first offer to acquire the assets before they hit the open market.

Where reports disagree

Early coverage of the transaction generated specific inconsistencies regarding the flow of capital and the exact size of the medical portfolio.

Initial wire feeds and morning media headlines published on October 13 reported that BlackRock was purchasing a stake directly from Humana for $2.8 billion. Reuters published a correction later on October 13 to clarify the exact mechanics of the capital transfer. The official Humana Form 8-K filed on October 13 specifies that BlackRock is acquiring the equity stake exclusively from Welsh, Carson, Anderson & Stowe. Humana retains its existing minority stake and operating control. The insurer does not receive any portion of the $2.8 billion transaction proceeds. The insurer also does not pay any transaction proceeds to the departing private equity sponsor.

The exact scale of the physical clinic network also produced conflicting figures in financial databases. The primary SEC Form 8-K and the Humana press release distributed on October 13 document a network of “nearly 150” CenterWell Senior Primary Care clinics. Certain regional publications and the equity market summary provider Minichart reported the network size as “nearly 100” clinics on the morning of October 13. The discrepancy likely stems from a failure to count clinics currently under construction or recently opened locations that have not yet begun accepting full Medicare Advantage patient panels. The SEC filing remains the authoritative source on the total asset count transferred in the joint venture restructuring.

The Humana Form 8-K filed on October 13, 2026, confirms the final equity purchase price stands at exactly $2.8 billion.